Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 1, 2012

View Archived Issues

Kyowa Hakko Kirin withdraws Japanese submission for Nesp

Tyrosine-protein kinase SYK inhibitors may counter retinoblastoma

Roche prepares new HCV NS5B inhibitors

Researchers at Gilead Sciences prepare novel sodium channel blockers

Gilead Sciences discloses new agents for HIV infection

Novel DNA-dependent protein kinase inhibitors claimed by Merck KGaA

Korean scientists prepare novel compounds with muscle relaxant activity

New treatment for rosacea designed by Galderma Pharma

Marker of multiple sclerosis duration identified in cerebrospinal fluid

Study identifies markers of treatment response in ovarian cancer

NanoViricides submits pre-IND briefing document to FDA for FluCide

Ampion demonstrates improvement in pain relief in osteoarthritis

AcelRx Pharmaceuticals gives update on ARX-01

FDA accepts NPS Pharmaceuticals' NDA for teduglutide

Spectrum Pharmaceuticals in-licenses long-acting granulocyte colony-stimulating factor

TGen and University of Arizona receive funding for cancer research

Astellas and UCB sign Japanese development and commercialization agreement for Cimzia

Janssen seeks approval for Velcade subcutaneous injection in Japan

Juventas Therapeutics reports 1-year data for JVS-100

Pfizer recaps progress of 2011

Starpharma's dendrimer-docetaxel formulation shows superiority to docetaxel in breast cancer model

FDA approves ivacaftor for rare form of cystic fibrosis

TiGenix's study of Cx-611 in rheumatoid arthritis cleared to open final cohort

Mesoblast receives FDA clearance to conduct stem cell therapy study in diabetes

NIH joins phase II tuberculosis vaccine trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...